Dear Colleagues,
OncoAlert 🚨is Proud to be collaborating with @AUC3_Official and will be coming LIVE from Miami🌴 in January for #AUC3 2026

ARTICLE HERE: 👉 buff.ly/ULensJm

Here is one of the co Organizers @DrChoueiri 🇺🇸 To tell us about the #AUC3 publication
JUST OUT

OncoAlert🚨 #AUC3 Week 2026
Presenter Dr. Daniel Heng 🇨🇦
Treatment duration: Continuous therapy in mRCC #KidneyCancer

ARTICLE HERE: 👉https://buff.ly/bAgkPQC
JUST OUT on the management of renal cell and urinary tract cancers from the Advanced Urologic Cancer Consensus Conference

OncoAlert🚨 #AUC3 Week 2026
Their Publication is NOW OUT
ARTICLE HERE: 👉 buff.ly/bAgkPQC

Presenter Dr. Michael Atkins🇺🇸
Adjuvant Therapy Debate in #KidneyCancer : PRO

OncoAlert🚨The #AUC3 WEEK 2026
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC

Presenter Dr. Brian Rini 🇺🇸
(Adjuvant Therapy Debate) CON in #KidneyCancer RCC

OncoAlert🚨The #AUC3 WEEK 2026
Their Publication is NOW OUTARTICLE HERE: 👉 buff.ly/bAgkPQC
Presenter: Cristina Suarez 🇪🇸 Treatment Strategy for Very Favorable and Favorable Risk Disease #kidneyCancer

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026

Presenter Dr. Abhishek Tripathi : Treatment Selection after IO resistance debate: Targeted Therapy approach

Conclusion:
Erdafitinib remains the only targeted therapy with level 1 evidence demonstrating superior OS

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026

Presenter Dr. Michiel Van Der Heijden : Treatment Selection after IO resistance debate: Chemotherapy approach

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Matthew Milowsky 🇺🇸 Targeted Therapy Toxicity Management: From Prevention to Treatment

Targeted therapeutics in urothelial cancer are associated with distinct toxicities that require important preventive measures and specific tx protocols.

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Andrea Apolo

Summary of the Approach to Variant Histology Urinary Tract Tumors Mixed UC variant histologies (except for small cell) are managed as conventional urothelial carcinoma

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Jacqueline Brown 🇺🇸 Optimal sequencing after EV-pembrolizumab progression

Remaining Q's
In patients who stop EV-P due to tox +/- CR, who can rechallenge?
• With EV? With other Nectin-4 targeting agents?ADCs, bicycle molecules,
RLT, CAR-T

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Daniel Petrylak 🇺🇸 Optimizing EV use: Dosing strategies, patient selection & toxicity management

EV Dosing Strategy Conclusions:
Most common side effects of Enfortumab treatment include hyperglycemia, neuropathy, skin rash and pneumonitis

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Stephanie Berg 🇺🇸 EV + pembrolizumab post adjuvant IO progression

Concluding Thoughts:
Defining Primary Refractory Disease & Resistance Mechanisms

Is sustained PD-(L)1 inhibition necessary to improve outcomes?

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Leslie Ballas 🇺🇸 Application of bladder-sparing approaches: Technical advances & patient selection #Bladder Cancer

-changing systemic therapy necessitates changes in treatment paradigms

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Joaquim Bellmunt 🇺🇸 Use of ctDNA for treatment selection and response monitoring: Con

Key limitations of ctDNA in genitourinary cancers

Low sensitivity and false negatives in low–tumor burden, localized, and MRD settings

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Alexandra Drakaki 🇺🇸 Use of ctDNA for treatment selection and response monitoring (PRO)

cDNA: More questions than answers
* Does Early Detection mean shorter survival?
* Is Early Intervention an Overreaction? How Early is TOO
Early?

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. David Aggen 🇺🇸 Evidence-based adjuvant approaches NMIBC #Bladder Cancer

Adjuvant Therapy for High Risk Bladder Cancer
Adjuvant immunotherapy is SOC in patients with high-risk disease at cystectomy

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Joshua Meeks 🇺🇸 Cased based panel discussion #BladderCancer

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Todd Morgan 🇺🇸 Biomarkers and technology integration in NMIBC #BladderCancer

Biomarker data are good-enough for clinical integration
Implementation requires a workflow overhaul
Realistic goal is alternation, not full replacement

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026
Presenter Dr. Roger Li 🇺🇸 Personalized therapy in the post-BCG setting #BladderCancer

BCG Unresponsive NMIBC defines disease no longer responding to BCG
SOC for BCG exposed NMIBC should be repeat BCG

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026 Urinary Tract Tumors
Presenter Dr. Wesley Yip 🇺🇸 Risk stratification and treatment selection for intermediate-risk NMIBC #BladderCancer

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer
Presenter Dr. Pedro barata 🇺🇸 Multimodal approaches for challenging metastatic sites: Combining treatment with site-specific interventions (bone, brain, pleural disease)

Certain metastatic sites matter disproportionately: Bone/brain/pleural

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer
Presenter Dr. Ari Hakimi 🇺🇸 Approach to oligoprogressive disease

Local treatment for metastatic disease may remain a viable strategy in a subset of patients

Risk factors for earlier disease recurrence
CNS or Liver at presentation
Male sex

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer
Presenter Dr. Chad Tang 🇺🇸 Approach to oligometastatic disease

There is a spectrum of disease phenotypes in metastatic RCC with some patients exhibiting indolent omRCC

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer
Presenter Dr. Brian Shuch 🇺🇸 Cytoreductive nephrectomy for advanced disease: Con

Patients need control of their systemic disease & our better systemic therapy offers that
Surgery upfront is rarely needed, and we have other ways to palliate

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer
Presenter Dr. Philip Pierorazio 🇺🇸 Cytoreductive nephrectomy for advanced disease: Pro

Surgery for Metastatic Renal Cell Carcinoma
Systemic therapy first, but… Cytoreductive nephrectomy remains a valuable tool in the management of M+RCC.

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer
Presenter Dr. Aly-Khan Lalani 🇨🇦 Lifestyle medicine in RCC: Evidence-based approaches to nutrition, physical activity, & microbiome optimization

lifestyle measures in RCC
• Early, unintentional weight loss is a simple, actionable signal

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 : Cristina Suarez 🇪🇸
👉 youtu.be/NXofn5Jc_mc
Treatment Strategy for Very Favorable and Favorable Risk Disease #kidneyCancer

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer
Presenter Dr. Thai Ho🇺🇸 Practical approaches to mastering IO-TKI adverse event detection & management

G2 AEs, hold TKI initially (shorter t1/2 than IO), AE may resolve after ~4 half-lives

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #kidneyCancer
Presenter Dr. Daniel Heng 🇨🇦 Treatment duration: Continuous therapy

Continuous Therapy in mRCC
1. All Phase III registration trials employ continuous therapy
Exception: Pembro is stopped at 2 years which is a specific subgroup of responders

🚨 OncoAlert | #AUC3 2026 – Adjuvant Therapy Debate (PRO)🎤 Dr. Michael Atkins 🇺🇸
👉 youtu.be/1Ay18rPlW4s

✔️ Appropriate for all except lowest-risk pts (T3a, Fuhrman 1–2)
⚠️ Dual IO (Durva/Treme or Nivo/Ipi) may fit highest-risk pts, but toxicity is a concern
Does pembro + belzutifan prevent relapse?